Objectives: This descriptive, cross-sectional study aimed at evaluating the prevalence of G6PD deficiency, the 376A → G, 202G → A single nucleotide polymorphisms (SNPs) among HIV patients attending care at a teaching hospital in Ghana and determine if the SNPs are associated with a deranged hematological profile. Results: Out of the 200 participants, 13.0% (26/200) were G6PD deficient based on the methemoglobin reductase technique, with 1.5% (3/200) and 11.5% (23/200) presenting with partial and full enzyme defect, respectively. Among the 13.0% participants with G6PD deficiency, 19.2% (5/26), 30.8% (8/26), and 19.2% (5/26) presented with 376A → G only [Enzyme activity (EA): 1.19 U/g Hb], 202G → A only [EA: 1.41 U/g Hb], and G202/A376 SNPs [EA: 1.14 U/g Hb], respectively. Having the 376A → G mutation was associated with lower red blood cell (RBC) count [3.38 x106/µL (3.16-3.46) vs 3.95 x106/µL (3.53-4.41), p=0.010], but higher mean cell volume (MCV) [102.90 (99.40-113.0) vs 91.10 fL (84.65-98.98), p=0.041] and mean cell hemoglobin (MCH) [33.70 pg (32.70-38.50) vs 30.75 pg (28.50-33.35), p=0.038] whereas possessing the 202G → A mutation was associated with higher MCV only [98.90 fL (90.95-102.35) vs 91.10 fL (84.65-98.98), p=0.041] compared to G6PD non-deficient participants.
Introduction
Human Immunodeficiency virus (HIV) is a chronic viral infection and a serious public health concern. Currently, approximately 37.9 million people are living with HIV worldwide [1] . In Ghana, 330 000 people are living with HIV [2] .
HIV infection is associated with persistent inflammation and immune activation leading to production of reactive oxygen molecules and oxidative stress [3, 4] . Additionally, HIV positive individuals are predisposed to a plethora of other infections which may result in oxidative stress. The sequelae of these oxidative stress are particularly alarming and lifethreatening in people comorbid with Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency. The prevalence rate of G6PD deficiency is 5-25% in tropical Africa and Asia [5] [6] [7] . In Ghana, the prevalence of G6PD deficiency is 15-26% [8, 9] .
Over 400 G6PD variants have been identified [10] and the polymorphisms are predominantly defined to specific geographic locations [11] . About 186 of these variants are associated with G6PD deficiency due to decreasing enzyme activity or stability [5, 12, 13] . In sub-Saharan Africa, the predominant G6PD variants are B, A, and A-, with frequencies greater than 1% [14] . The G6PD B variant possesses the 376A cDNA sequence and has been shown to have normal enzyme activity. Likewise, the G6PD A variant, which carries a cDNA mutation A376G, has about 85% of the normal enzyme activity. On the contrary, the G6PD A-variants carry the G6PD A backbone with an added single nucleotide mutation. The most common G6PD A-variant possesses the A376G/G202A mutation and has been reported to have 10% of normal enzyme activity in their red blood cells (RBC), although their white blood cells (WBC) maintain 100% normal enzyme activity [15] . Other A-variants peculiar to sub-Saharan Africa are the A376G/T968C, A376G/G680T, and A376G/A543T [16] .
In some conditions such as malaria, before primaquine administration, G6PD deficiency is screened for. However, the advantage of screening HIV positive patients for G6PD deficiency is often overlooked despite reports indicating worse clinical outcomes in people comorbid with HIV and G6PD deficiency [17] [18] [19] . Importantly, HIV and G6PD deficiency have individually being linked with deranged hematological profile. HIV affects all hematological cell lines, as evidenced by anaemia, neutropaenia, lymphopaenia, and thrombocytopaenia [20] [21] [22] [23] whereas G6PD deficiency is associated with attenuated levels of haemoglobin (Hb), haematocrit (HCT), mean cell volume (MCV), and mean cell haemoglobin (MCH) [24] . Notwithstanding, studies on G6PD deficiency in HIV patients is limited in Africa, where both conditions are prevalent and none has been conducted in
Ghana.
This study, thus, aimed at evaluating the prevalence of G6PD deficiency, the 376A → G, 
Study Population
The sample size for the study was calculated using Fischer's sampling formula ( = 2 / 2 ), where is the critical value of the normal distribution (1.96 at 95% CI); is the estimated prevalence of G6PD deficiency in Ghana (15%) [8] ; is the absolute precision or sampling error tolerated = 5%. From the above equation, a total of 200 consecutive consenting HIV positive Ghanaians, aged 15 years and above, were recruited during their routine clinic visit days. All participants were on ART. Participants on sulfate and copper containing medications, those who were very ill and pregnant women were exempted from the study. Participants' selection protocol is shown in Additional file 1: Fig. S1 .
Sample collection and assay
Six milliliters (6 ml) of venous blood was obtained from each participant under aseptic conditions for laboratory assessments. Complete blood count was evaluated using XN 6 G6PD screening was performed with the methemoglobin reductase technique as described by Brewer et al. [25] and patients were grouped into "normal", "partial defect" and "full defect" based on the color of the test solution as described by Antwi-Baffour et al. [26] (Details in Additional file 1: Table S1 ). G6PD enzyme activity assay was done for samples that were G6PD deficient (both "full" and "partial defect") during screening by the methemoglobin reductase technique using the Pointe Scientific G6PD kinetic kit according to manufacturer's instructions (Standardized with an intra-assay % CVs of 2.5%-9.2% and inter-assay %CVs of 2.1%-11.4%) (Pointe Scientific Limited, UK). In preparation for G6PD genotyping, DNA was extracted from the blood samples that were G6PD deficient during screening. Extraction was based on the double salt precipitation method as previously described [27] . A large number of single nucleotide polymorphisms (SNPs) have been identified to be associated with G6PD deficiency in Africa [10, 11, 16] . However, 376A → G, 202G → A SNPs are the most commonly reported in Ghana [14, 28] and were thus selected for this study. For the 376A → G mutation, the forward and reverse primer sequences used were 5'-CCCAGGCCACCCCAGAGGAGA-3′ and 5'-CGGCCCCGGACACGCTCATAG-3′, respectively whereas those for the 202G → A mutation were 5'-CACCACTGCCCCTGTGACCT-3′ and 5'-GGCCCTGACACCACCCACCTT-3′, respectively 202G → A only, and G202/A376 SNPs, respectively (Fig. 2b) . Upon stratification by sex, 4, 7, 4, and 5 of the females, and 1, 1, 1, and 2 of the males had the 376A → G only and 202G → A only, G202/A376 SNPs, and no band, respectively (Fig. 2c) . The likelihood of being phenotypically classified as G6PD full defect was higher among participants having the G202/A376 SNPs compared to the 202G → A SNP (Additional file 1: G6PD variants (Fig. 3 ).
Discussion
This study reports a 13.0% prevalence of G6PD deficiency, comprising 5% and 11.5% partial and full enzyme defect, respectively, based on methemoglobin reductase technique. Our finding is consistent with a retrospective study by Tungsiripat et al. among HIV patients in the United States. After screening 212 Blacks infected with HIV, they found 28 (13.2%) to be G6PD deficient [30] . In another study by Serpa et al. [31] in the United States, 6.8% of all HIV-infected adults had G6PD deficiency which is lower compared to this present study. The disparity in the prevalence rates could be linked to the fact that Serpa et al. included participants of diverse race (African Americans, Hispanics, Whites and Asian-Pacific). Evidence suggests that the prevalence of G6PD deficiency is very low among whites compared to blacks [30, 32] . Thus, the inclusion of Caucasians may have attenuated the prevalence rate found in their study. Our finding also falls within the prevalence range of 5-25% found in tropical Africa, the Middle East, tropical and subtropical Asia, some parts of the Mediterranean, and in Papua New Guinea [5] [6] [7] .
In this study, among the participants with G6PD deficiency, we found 19.2% to harbor the G6PD A-allele (G202/A376) which is associated with reduced enzyme activity [15] . A study by Xu et al. in the Dominican Republic also reported a similarly high prevalence of the G6PD A-variant among HIV-infected patients [33] . Of note, we also observed that, among those with G6PD deficiency based on the methemoglobin reductase technique, 30.8%
presented with no band on electrophoresis. It is possible that these patients harbored other G6PD variants such as the A376G/T968C, A376G/G680T, and A376G/A543T which are also peculiar to sub-Saharan Africa [16] . Importantly, seven and four of the females versus one and two of the males had the G6PD A and G6PD A-allele, respectively. Congruently, more females than males with the G6PD A-variants have been reported in previous studies in Ghana [14, 28] . An explanation could be the higher number of females in this study compared to males. The consistently higher number of HIV positive females compared to males in Kumasi justifies the gender disparity [34, 35] .
Another finding of this study is that the presence of only the 376A → G mutation was associated with lower RBC count, but higher MCV and MCH whereas possessing only the 202G → A mutation was only associated with significantly higher MCV. The relatively greater deranged hematological profile in the participants with the 376A → G compared to the 202G → A could be attributed to the comparatively lower G6PD enzyme activity among participants with the 376A → G mutation compared to the 202G → A mutation, although not statistically significant (Additional file 1: Fig. S3 ). In a study to find the association between G6PD deficiency and hematological parameters in children from Botswana, Motshoge et al. made similar observations [36] . The increased MCV due to the 202G → A mutation is also in harmony with a GWAS study by Ding et al. [37] . Other reports such as those by Ajlaan [38] and Domingos et al. [39] are in line with our study findings.
Conclusion
This study reports a 13.0% prevalence of G6PD deficiency, comprising 1.5% and 11.5% partial and full enzyme defect, respectively, based on the methemoglobin reductase technique among HIV patients in Ghana. Among G6PD deficient HIV patients, the prevalence of G202/A376 SNPs is 19.2%. The 376A → G mutation is associated with lower RBC count, but higher MCV and MCH whereas the 202G → A mutation is associated with higher MCV.
Limitations
Unavailability of data on important modifying genotypes such as HbS; alpha-thalassemia 3.7 deletion as well as data on ART; its adherence and CD4 count is a limitation of this study. This study is also limited by the relatively small sample size and the cross-sectional design used which precluded comparison with non-HIV group. Larger sample sizes in future studies will be ideal. Technology. Written informed consent was obtained from all participants who opted to participate after the aims and objectives of the study was explained to them.
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Not applicable. Figure 1 Prevalence of G6PD deficiency. (a) Phenotypic prevalence of G6PD deficiency based on methemoglobin reductase technique (b) Genotypic prevalence of 376A → G, 202G → A, G202/A376 G6PD variants (c) Genotypic prevalence of 376A → G, 202G → A, G202/A376 G6PD variants by sex.
Figures
Figure 2
Comparison of hematological parameters by G6PD genotype.
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